Days after leaving the hospital, President Trump is urging regulators to approve emergency use authorization of Regeneron’s (REGN) and Ell Lilly’s (LLY) treatments.
He specifically noted that the REGN cocktail was key to his successful treatment.
“We have hundreds of thousands of doses that are just about ready,” Trump said. “I have emergency use authorization all set and we got to get it signed now. And you’re going to get better, you’re going to get better really fast.”
At the same time, Eli Lilly just announced it submitted a request for emergency use authorization of its LY-CoV555 monotherapy. The company anticipates it could supply as many as 100,000 doses by the end of October, and up to a million by the end of the year.
“We expect to submit a subsequent request for EUA for combination therapy in November, pending clinical trial enrollment, once additional safety data accumulate and sufficient supply is manufactured,” the company added. “Lilly anticipates having data to support a biologics license application submission for combination therapy as early as [the second quarter of] 2021. Conversations with global regulators are ongoing.”
According to Fox Business, “Trump added that the administration intends to make Regeneron and Eli Lilly’s treatments free for patients, suffering from the virus, especially seniors.”
At the moment, shares of REGN are up $12.17 to $603.86. Shares of LLY are up $3.58 to $152.